TY - JOUR
T1 - ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage
AU - Scielzo, C.
AU - Camporeale, A.
AU - Geuna, M.
AU - Alessio, M.
AU - Poggi, A.
AU - Zocchi, M. R.
AU - Chilosi, M.
AU - Caligaris-Cappio, F.
AU - Ghia, Paolo
PY - 2006/4
Y1 - 2006/4
N2 - ZAP-70 tyrosine kinase is involved in signalling pathways following T-cell receptor stimulation and was originally described only in T cells and natural killer cells. ZAP-70 expression has been reported in normal mouse B lineage cells and in human malignant B lymphocytes, mainly in chronic lymphocytic leukemia (CLL) where it correlates with clinical outcome. We analyzed several B-cell lines and ex vivo malignant B cells, ranging from acute lymphoblastic leukemia to multiple myeloma and reflecting different stages of B-cell differentiation, and they showed ZAP-70 expression regardless their maturation stage. We then analyzed by Western blot and flow cytometry different human normal B-lymphocyte subpopulations: naïve, germinal center and memory B cells from tonsils, CD19+ CD5+ cells from cord blood and CD19+ lymphocytes from peripheral blood. All expressed ZAP-70 protein, though at different levels depending on their differentiation, activation and tissue localization. In addition, ZAP-70 expression levels could be modulated following stimulation via the B-cell receptor. These findings implicate a potential role of ZAP-70 in the signalling pathway of B lymphocytes at different maturational stages, indicate that ZAP-70 expression is not a CLL-specific feature among B-cell malignancies and suggest that the absence of ZAP-70 rather than its presence should be considered abnormal for malignant B lymphocytes.
AB - ZAP-70 tyrosine kinase is involved in signalling pathways following T-cell receptor stimulation and was originally described only in T cells and natural killer cells. ZAP-70 expression has been reported in normal mouse B lineage cells and in human malignant B lymphocytes, mainly in chronic lymphocytic leukemia (CLL) where it correlates with clinical outcome. We analyzed several B-cell lines and ex vivo malignant B cells, ranging from acute lymphoblastic leukemia to multiple myeloma and reflecting different stages of B-cell differentiation, and they showed ZAP-70 expression regardless their maturation stage. We then analyzed by Western blot and flow cytometry different human normal B-lymphocyte subpopulations: naïve, germinal center and memory B cells from tonsils, CD19+ CD5+ cells from cord blood and CD19+ lymphocytes from peripheral blood. All expressed ZAP-70 protein, though at different levels depending on their differentiation, activation and tissue localization. In addition, ZAP-70 expression levels could be modulated following stimulation via the B-cell receptor. These findings implicate a potential role of ZAP-70 in the signalling pathway of B lymphocytes at different maturational stages, indicate that ZAP-70 expression is not a CLL-specific feature among B-cell malignancies and suggest that the absence of ZAP-70 rather than its presence should be considered abnormal for malignant B lymphocytes.
KW - B lymphocytes
KW - B-lymphoid malignancies
KW - Chronic lymphocytic leukemia
KW - ZAP-70
UR - http://www.scopus.com/inward/record.url?scp=33646472451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646472451&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404138
DO - 10.1038/sj.leu.2404138
M3 - Article
C2 - 16482211
AN - SCOPUS:33646472451
VL - 20
SP - 689
EP - 695
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 4
ER -